Vaccinia virus (VV) produces two antigenically and structurally distinct infectious virions, intracellular mature virus (IMV) and extracellular enveloped virus (EEV). EEV is important for the efficient dissemination of virus both in vivo and in vitro where it causes formation of comet-shaped virus plaques. Here, we show that EEV, in contrast to IMV, is resistant to neutralization by antibodies bound to its surface. However, antibodies against EEV can prevent comet formation in cell culture. To explain this apparent paradox, we investigated the mechanism by which antibodies inhibit comet formation and demonstrated that antibodies prevent EEV
Introduction
Vaccinia virus (VV) produces large and complex virions that contain a double-stranded DNA genome and more than 100 polypeptides (Essani & Dales, 1979) . There are two morphologically distinct infectious forms of virions, termed intracellular mature virus (IMV) and extracellular enveloped virus (EEV) (Appleyard et al., 1971 ; Ichihashi et al., 1971) . IMV represents the majority of infectious progeny and remains within the cytoplasm of the infected cell until cell lysis. However, a fraction of IMV becomes further enveloped by a double membrane derived from cellular membranes to form intracellular enveloped virus (IEV) (Tooze et al., 1993 ; Schmelz et al., 1994) . Some IEV is propelled by polymerization of actin comets to the cell surface (Cudmore et al., 1995) , where the outermost membrane fuses with the plasma membrane releasing EEV from the cell. With most strains of VV [International Health Department-J (IHD-J) strain is an exception] much of the EEV remains attached to the cell surface and is termed cell-associated enveloped virus (CEV) (Blasco & Moss, 1992) .
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Fax j44 1865 275501. e-mail glsmith!molbiol.ox.ac.uk release from infected cells, and consequently comet formation, by agglutination of the virus on the cell surface. Two complementary observations allow this conclusion : first, electron microscopy showed that infected cells incubated with medium containing anti-vaccinia virus antibodies have virus aggregates on their surface ; second, culture medium from these cells contained a 4 log 10 fold reduction in the physical particle/ml titre in comparison with control culture. A mechanism by which antibodies to EEV proteins provide immunological protection is thus restriction of EEV release rather than neutralization of free EEV particles.
At least 10 proteins which are absent from IMV are associated with the outer envelope of EEV (Payne, 1978 (Payne, , 1979 . Six genes are known to encode proteins present in the EEV outer envelope. These are A56R, encoding the virus haemagglutinin gp86 (Payne & Norrby, 1976 ; Shida, 1986) ; F13L, encoding a protein with a molecular mass of 37 kDa, p37 (Hirt et al., 1986) ; A34R, encoding a triplet of glycoproteins, gp22-24 (Duncan & Smith, 1992) ; B5R, encoding a 42 kDa glycoprotein, gp42 (Engelstad et al., 1992 ; Isaacs et al., 1992) ; A36R, encoding a 45-50 kDa protein, p45-50 (Parkinson & Smith, 1994) ; and A33R, encoding a 23-28 kDa protein, gp23-28 (Roper et al., 1996) . These proteins endow EEV with different biological and immunological properties (Boulter, 1969 ; Appleyard et al., 1971 ; Turner & Squires, 1971 ; Boulter & Appleyard, 1973) .
Recently, it has been demonstrated in vitro that EEV and IMV bind to distinct receptors (Vanderplasschen & Smith, 1997) , and in contrast to a previous study (Doms et al., 1990) it has been suggested that they may enter cells by different mechanisms (Ichihashi, 1996) . EEV is important for the efficient dissemination of virus both in vivo and in vitro (Appleyard et al., 1971 ; Boulter & Appleyard, 1973 ; Payne, 1980 ; Payne & Kristensson, 1985) . The importance of EEV was emphasized by passive transfer of immunity with antibodies to EEV proteins better than antibodies to IMV (Appleyard et al., 1971 ; Turner & Squires, 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974 ; Payne, 1980) . Strains of virus yielding higher amounts of EEV (for example IHD-J strain) produce comet-shaped virus plaques if incubated under liquid overlay in cell culture, the head of the comet being formed by the primary plaque and the tail by a series of secondary plaques (Appleyard et al., 1971) . These comets are prevented by polyclonal antibodies against EEV but not IMV proteins (Appleyard et al., 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974 ; Payne, 1980) . Similarly, Engelstad et al. (1992) showed that a monospecific polyclonal antibody against the EEV B5R protein was able to prevent comet formation. Although direct evidence was lacking, the mechanism of comet inhibition was supposed to be by neutralization of released EEV as several early studies claimed antibody-mediated neutralization of EEV (Appleyard et al., 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974 ; Payne, 1980) . Recently, Ichihashi (1996) showed that fresh intact EEV taken from the supernatant of infected cells was resistant to neutralization by antibodies. This observation generated an obvious paradoxical question which was not addressed : how can antibodies inhibit comet formation without being able to neutralize EEV? Here, we confirm Ichihashi's observation that fresh intact EEV taken from the supernatant of infected cells is resistant to antibody neutralization and elucidate the mechanism by which antibodies prevent comet formation. The data show that antibodies induce agglutination of virus on the cell surface, and consequently, inhibit EEV release and comet formation. A mechanism by which antibodies to EEV proteins provide immunological protection is thus restriction of EEV release rather than neutralization of free EEV particles.
Methods
Cells and virus. RK "$ cells (rabbit kidney cells, ATCC CCL-37) were grown in minimum essential medium (MEM) (Gibco) supplemented with 10 % heat inactivated (for 30 min at 56 mC) foetal bovine serum (HFBS). The IHD-J VV strain was used in this study. Purified IMV and fresh EEV were prepared as described previously (Vanderplasschen & Smith, 1997) . Briefly, for fresh EEV, cells were infected at an m.o.i. of 1 p.f.u. per cell, and then washed and overlaid with MEM containing 2n5 % HFBS. The culture supernatant was harvested 24 h post-infection (p.i.) and centrifuged to remove detached cells and cell debris (1000 g, 20 min, 4 mC). After appropriate dilution in PBS (3 mM KCl, 1n5 mM KH # PO % , 0n14 M NaCl, 6n5 mM Na # HPO % , pH 7n2) containing 2 % HFBS any contaminating IMV infectivity was neutralized by addition of monoclonal antibody (MAb) 5B4\2F2 (final dilution of 1\2560) against the 14 kDa fusion protein (A27L gene product) of IMV (Czerny & Mahnel, 1990) . This concentration of MAb 5B4\2F2 neutralized more than 96 % of the infectivity of purified IMV in the conditions used in this study. A fresh EEV preparation was produced before each experiment.
Sera and MAbs against VV. Different sera and MAbs against VV were used in this study (listed in Table 1 ). A human serum was obtained from a 41-year-old male who had been repeatedly immunized against VV. A rat serum was obtained from an animal which had been immunized 
* The arbitrary titre in antibody against VV of the different sera and MAbs was determined by indirect immunofluorescent staining as described in Methods.
subcutaneously three times at 3 week intervals with 50 µg of psoralen-UV inactivated (Hanson et al., 1978) purified EEV of VV strain IHD-J. The serum was collected 3 weeks after the last immunization. A rabbit serum was a mixture (1 : 1) of the sera of two animals which had been intradermally inoculated with 10' p.f.u. of Western Reserve (WR) VV strain. After 5 weeks, the animals were reinoculated intradermally with 10( p.f.u. ; 2 weeks later the animals were bled. Murine serum was a pool of sera of BALB\c mice that were inoculated intranasally with VV strain Copenhagen as described elsewhere (Alcamı! & Smith, 1996) ; 5 weeks later the mice were inoculated intranasally with 10( p.f.u. of WR strain and were bled 10 days later. Cell culture supernatant of hybridoma cells secreting murine MAb 1H831 (Shida, 1986) and rat MAb 19C2 (Schmelz et al., 1994) raised against haemagglutinin and B5R EEV surface proteins, respectively, were also used. All sources of antibodies were heated for 30 min at 56 mC to inactivate complement and were stored in aliquots at k70 mC until use. The titre of anti-VV antibody in sera and hybridoma cell culture supernatants was determined by indirect immunofluorescent staining of fixed and permeabilized VV-infected cells. The titre represents the highest dilution tested which gave an optimal fluorescent signal.
Antibody neutralization assay. Purified IMV or fresh EEV (between 300 and 400 p.f.u.\ml) in PBS containing 2 % HFBS were incubated for 1 h at 37 mC with preimmune (negative control, serum from homologous species lacking antibodies against VV) or immune serum, or with hybridoma cell culture medium (negative control) or supernatant of hybridoma secreting cells. The virus was then adsorbed onto RK "$ cells grown in six-well cluster dishes (0n5 ml per well) for 1 h at 37 mC. After washing with PBS containing 2 % HFBS, the cells were overlaid with MEM containing 2n5 % HFBS and 1n5 % carboxymethyl cellulose (CMC) (Mackett et al., 1985) . After 2 days, the cells were stained with 0n1% crystal violet in 15 % ethanol and the plaques were counted.
Comet inhibition assay. RK "$ cells grown in six-well cluster dishes were infected for 1 h at 37 mC with purified IMV (about 50 p.f.u. per well). After washing with MEM containing 2 % HFBS, the cells were overlaid with 2n5 ml per well of the same medium. After an incubation period of 1 h, immune or preimmune serum (negative control) was added to the medium. The cells were incubated for 2 days at 37 mC and then stained with crystal violet.
Preparation of cells for electron microscopy. Cells were treated as described elsewhere (Sanderson et al., 1996) . Sections were cut parallel to the surface of the dish, contrasted with lead citrate and examined in a Zeiss Omega EM 912 electron microscope.
Determination of p.f.u./ml or physical particle/ml titres. Virus infectivity (p.f.u.\ml) was titrated by plaque assay. RK "$ cells grown in six-well cluster dishes were incubated in duplicate with serial 10-fold dilutions of the virus in PBS containing 2 % HFBS (0n5 ml per well) for 1 h at 37 mC, washed with PBS containing 2 % HFBS and overlaid with CMC in MEM containing 2n5 % HFBS (Mackett et al., 1985) . After 2 days, the cells were stained with crystal violet and the plaques were counted. Titres were expressed as the mean of the duplicate measures. Physical particle\ml was determined as described previously (Vanderplasschen & Smith, 1997) with minor modifications. Briefly, the VV preparation to be titred was sonicated at 40 µm for 30 s, then serially 10-fold diluted in distilled water. One µl of each dilution and of the original sample was then loaded in triplicate on the surface of a glass coverslip coated with fibronectin (washed with distilled water and dried beforehand). After complete drying, the virions were fixed to the fibronectin with 4 % paraformaldehyde in PBS for 30 min on ice and then permeabilized in ethanol-PBS (90 : 10, v\v) for 2 min at 0 mC. After extensive washing with PBS and a final wash step with distilled water, the samples were mounted in Mowiol-DAPI mounting medium as described previously (Vanderplasschen & Smith, 1997) . This mounting medium contained 1 µg\ml of DAPI. The numbers of particles revealed by DAPI fluorescence were then counted on the entire area corresponding to each drop. The mean number of the three measurements multiplied by the dilution factor enabled the number of particles\ml to be calculated. This assay could not quantify particles at less than 10$ physical particles\ml.
Statistical analysis. Student's t-test was used to test for the significance of the results (P 0n05).
Results
Intact EEV are resistant to antibody neutralization EEV is an IMV particle with an additional outer membrane containing proteins that are absent from IMV, which explains why IMV-neutralizing antibodies fail to inhibit the infectivity of EEV particles. The EEV outer membrane is a loose and extremely fragile structure (Roos et al., 1996) . EEV purification, sonication or one cycle of freeze-thawing induce rupture of the EEV membrane and allow IMV-neutralizing antibodies to inhibit damaged EEV infectivity (Ichihashi, 1996 ; McIntosh & Smith, 1996 ; Vanderplasschen & Smith, 1997) . The integrity of the EEV outer membrane is crucial for investigation of its biological properties. This is particularly true for neutralization assays. The neutralizing activity of a MAb against an EEV protein could be obscured by infection mediated through IMV proteins exposed on damaged EEV. On the other hand, EEV neutralizing activity could be attributed to a polyclonal serum which in fact neutralized damaged EEV by targeting accessible IMV proteins. To avoid these problems, we prepared fresh EEV from the supernatant of infected cells and any con- taminating IMV or ruptured EEV was neutralized by addition of MAb 5B4\2F2 directed against the 14 kDa IMV protein (see Methods). The presence of this MAb throughout the assay also ensured that any EEV damaged during the assay is neutralized in both immune and preimmune (negative control) samples.
During our investigation of IMV and EEV binding and infectivity (Vanderplasschen & Smith, 1997) we failed to neutralize EEV infectivity using MAbs raised against EEV surface proteins. Here, different sources of antibody against VV antigens (four polyclonal sera and two MAbs) were tested for their potential to neutralize IMV and fresh EEV (Table 1) . No neutralization of EEV was observed with all the antibodies tested ; statistically similar numbers of plaques were obtained with controls and immune sera or MAbs (Table 1 neutralization was observed. The highest percentage of IMV neutralization was obtained with the immune rabbit serum, which had a titre of 1\800 and neutralized 98 % of IMV p.f.u.
Further experiments were performed with the rabbit serum as a source of antibodies against VV. This antiserum was selected for the following reasons : (i) this serum was a mixture of sera of two rabbits which had recovered from an experimental infection, and therefore should contain a variety of specific antibodies against VV ; (ii) this serum presented a high titre and a large volume was available.
As the rabbit antiserum was unable to neutralize EEV, it was necessary to demonstrate that it contained specific antibodies able to bind to EEV particles. To do this, fresh EEV (500 p.f.u.\ml) in PBS containing 0n2 % purified BSA (Sigma) was incubated with either preimmune or immune rabbit serum (final dilution of 1\100) for 1 h at 37 mC. At the end of the incubation period, protein A beads (Sigma) were added to both samples (final concentration of 30 mg\ml). After an incubation period of 30 min at 37 mC, the samples were centrifuged at 2000 g for 5 min and the supernatants were plaqued on RK "$ cells. Means of 287 (SD l 6n9, n l 3) and 7 (SD l 1n7, n l 3) p.f.u. were observed for preimmune and immune samples, respectively. This drastic reduction of p.f.u. demonstrated that immune rabbit serum contained specific antibodies able to bind to EEV particles. Similar observations were made with dilutions up until 1\1000 (data not shown).
Antibodies prevent comet formation but do not neutralize EEV
Antibodies against EEV antigens are able to prevent comet formation in cell culture and it was proposed that this inhibition was by neutralization of EEV released into the extracellular medium (Boulter & Appleyard, 1973) . The data presented above demonstrate that intact EEV are resistant to antibody neutralization. At first sight, these observations appear contradictory or suggest that antibodies could prevent comet formation without being able to neutralize EEV. To test this hypothesis, we investigated concurrently the ability of the rabbit immune serum to neutralize IMV (Fig. 1 a) or fresh EEV (Fig. 1 b) and to prevent comet formation (Fig. 2) .
In the range of dilutions tested (from 1\1000 to 1\100), statistically similar numbers of EEV plaques were observed with immune and preimmune sera, showing that the rabbit CAEE Resistance of EEV to antibody neutralization Resistance of EEV to antibody neutralization Fig. 3 . Antibodies induce virus agglutination on the cell surface. RK 13 cells grown in six-well cluster dishes were infected for 1 h at 37 mC (0n5 ml per well) with purified IMV (m.o.i. 0n1 p.f.u. per cell). After washing with MEM containing 2 % HFBS, the cells were overlaid with 2n5 ml per well of MEM containing 2 % HFBS. One hour later, preimmune (a, b) or immune (c, d) rabbit serum was added to the medium (1/100 final dilution). After an incubation period of 24 h at 37 mC, the cells were washed with PBS containing 2 % HFBS, and then fixed and processed for electron microscopy as described in Methods. Panels immune serum did not neutralize EEV (Fig. 1 b) . In contrast, IMV was efficiently neutralized. At a dilution of 1\1000, the rabbit immune serum still reduced IMV plaque number by 84 % (Fig. 1 a) and neutralization of 50 % of IMV p.f.u. was observed at dilution 1\3000 (data not shown).
Despite its inability to neutralize EEV, the rabbit immune serum did prevent comet formation in a dose-dependent manner (Fig. 2) . From dilutions of 1\1000 to 1\500 the size of the comets progressively decreased, while at dilutions of 1\250 and lower there was a complete inhibition of comets.
Preimmune serum at a dilution of 1\100 did not affect comet formation (Fig. 2 f ) .
Antibodies inhibit comet formation by preventing the release of EEV from infected cells
Comet formation can be divided into two consecutive phases. First, EEV is released from an infected cell into the cell culture medium and second, released EEV has to spread through the culture medium to infect other cells. Our results show that the latter phase cannot be neutralized by antibodies, Fig. 4 . Effect of antibody on the release of VV from infected cells. RK 13 cells grown in six-well cluster dishes were infected for 1 h at 37 mC (0n5 ml per well) with purified IMV (m.o.i. 0n1 p.f.u. per cell). After washing with MEM containing 2 % FBS, the cells were overlaid with 2n5 ml per well of MEM containing 2 % HFBS. One hour later, preimmune (#) or immune ($) rabbit serum was added to the medium (1/100 final dilution). At different times after infection (6, 12, 24 and 48 h), the supernatant of duplicate cultures was harvested and the p.f.u./ml (a) and physical particle/ml (b) titres were determined as described in Methods. Each value represents the mean for duplicate cultures. Error bars representing SD cannot be visualized on the graphs as their size was smaller than the symbol used. In (b), 10 3 means that the titre was below 10 3 physical particles/ml as the assay failed to detect any particle (see Methods). and therefore the mechanism by which antibodies inhibit comet formation must involve the former. As EEV surface epitopes are also expressed on the infected cell surface, one possible mechanism could be that antibodies inhibit the release of EEV from the infected cells by cross-linking EEV antigens on the virion and cell surface. To test this hypothesis, cells were infected and then overlaid with medium containing either immune or preimmune rabbit serum. At different times after infection (6, 12, 24, 48 h p.i.) , the cells were examined by electron microscopy (Fig. 3) and the p.f.u.\ml and physical particle\ml titres of virus in the cell supernatant were determined (Fig. 4) . Fig. 3 shows that anti-VV antibodies induced agglutination of virus on the cell surface. As early as 12 h p.i. the cells which were overlaid with medium containing immune rabbit serum showed virus aggregates on their surface (data not shown). The size and the abundance of these aggregates increased with time (data not shown) so that by 24 h p.i. very many virus particles were present on the cell surface (Fig. 3 c) . High magnification showed that cell surface aggregates were composed principally of virus but also involved membrane structures (Fig. 3 d) , which might represent fragments of disrupted EEV envelope. Cells infected and overlaid with medium containing preimmune rabbit serum had only a few EEV on their surface throughout the experiment as expected for the IHD-J strain (Blasco & Moss, 1992 ).
An alternative way to investigate release of EEV was to measure the number of infectious and physical particles in the cell culture supernatant. Fig. 4 shows that the presence of anti-VV antibodies in the extracellular medium leads to a drastic reduction of both p.f.u.\ml and physical particle\ml titres. At 24 h p.i., the p.f.u.\ml and physical particle\ml titres of cultures containing immune rabbit serum were 5 and 4 log "! lower, respectively, than titres observed with preimmune serum (Fig.  4) . We believe that the greater reduction in infectivity in comparison with physical particles may be explained by the presence of released virus aggregates in the supernatant.
Discussion
In this study we demonstrate that antibody against EEV proteins can prevent comet formation but cannot neutralize EEV infectivity. Early studies considered the ability of antibody to neutralize EEV by two methods : the neutralization assay and the anti-comet assay (Boulter & Appleyard, 1973) . When sera were concurrently applied to both assays the titre determined by neutralization assay (reciprocal of the serum dilution that neutralized 50 % of infectivity) was between 5 and 25 times higher than the anti-comet titre (reciprocal of the serum dilution that prevented completely comet formation) (Appleyard et al., 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974) . The range of anti-comet titre of sera from animals infected with live VV was about 1\200 to 1\400 (Appleyard et al., 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974 ; Payne, 1980) . Interestingly, the rabbit serum used in the present study exhibited an anti-comet titre of 1\250 (Fig. 2 d) , while serum dilution as low as 1\100 had no effect on EEV infectivity as determined by neutralization assay (Fig. 1) . Our results from the neutralization assay on EEV (Table 1 and Fig. 1 ) confirm the recent observation that intact EEV taken from the supernatant of infected cells is resistant to antibody neutralization (Ichihashi, 1996) . The opposite results described in early studies could be explained by the conditions used, which might not have retained the integrity of the EEV membrane before or during the assay, and consequently allowed damaged EEV to be neutralized by IMV-neutralizing antibodies. This possibility was not excluded by experiments that used sera depleted in antibody against IMV as they still retained some neutralizing activity against IMV (Boulter & Appleyard, 1973) . Interestingly, to our knowledge, there is no neutralizing MAb against EEV described so far (Payne, 1992 ; Roper et al., 1996) . However, these MAbs have been tested on purified EEV, and therefore it is possible that some neutralizing activity might have been obscured by infection mediated by exposed IMV proteins on the surface of damaged EEV.
The importance of EEV in VV virulence has been emphasized by several observations. Firstly, for most strains a positive correlation has been demonstrated between in vitro EEV yield and in vivo virulence (WR strain is one exception to this rule) (Payne, 1980) . Secondly, deletion of genes required for EEV production or specific infectivity leads to virus attenuation in vivo (Engelstad & Smith, 1993 ; Wolffe et al., 1993 ; Parkinson & Smith, 1994 ; McIntosh & Smith, 1996) . And thirdly, passive transfer of antibody against EEV proteins protects animals from virus challenge significantly better than antibodies to IMV (Appleyard et al., 1971 ; Turner & Squires, 1971 ; Boulter & Appleyard, 1973 ; Appleyard & Andrews, 1974 ; Payne, 1980) . The mechanism by which antibodies against EEV proteins are involved in the immune control of VV infection is not known. Here, we show in cell culture that antibody can prevent dissemination of EEV from infected cells by virus agglutination on the cell surface. It is attractive to speculate that this mechanism could also operate in vivo. However, it is also likely that antibodies against EEV proteins are involved in other mechanisms such as destruction of infected cells by antibody-dependent cell-mediated cytotoxicity. The contribution of complement in the immune control of VV infection is greatly diminished by a VV-encoded protein capable of inhibiting complement activation (reviewed by Isaacs & Moss, 1994) .
Unlike IMV, EEV is resistant to antibody neutralization. This biological difference between the two forms of VV was proposed to be the consequence of their different mode of entry (Ichihashi, 1996) . In contrast to a previous report (Doms et al., 1990) , Ichihashi (1996) suggested that IMV and EEV penetrate by membrane fusion and endocytosis, respectively. In this model, EEV entry consists of binding to the cell, endocytosis and disruption of the EEV outer membrane within endosomes releasing an infectious IMV which then binds to and fuses with the endosome membrane. Based on this model, the function of the EEV outer membrane is to protect the internal IMV from antibody neutralization and to mediate the binding on the cell surface. The fact that antibodies cannot neutralize EEV infectivity implies that they cannot inhibit EEV binding. Different hypotheses could explain this absence of inhibition. First, it is possible, but unlikely, that the EEV attachment protein(s) is not immunogenic and therefore that antibodies directed against this protein were not present in the sera used. Second, it is possible that, despite binding of antibodies on the EEV surface, the normal virus-cell interactions which mediate binding in the absence of antibodies can occur. Third, it is also possible that the binding of IgG-coated EEV is mediated by IgG-cellular receptor interactions as reported previously for other viruses (Mason et al., 1994 ; Wand et al., 1995) . Interestingly, if the latter hypothesis is true, EEV tropism could be different in the presence or absence of antibodies against EEV proteins. Experiments to investigate these possibilities are in progress.
